Shares of Moderna (NASDAQ: MRNA) climbed 4% on Monday after the biotechnology company announced three new vaccine development programs.
Moderna intends to use the lessons it learned with its coronavirus vaccine to advance its pipeline of drugs. The biotech will use its messenger RNA (mRNA) technology to develop vaccine candidates for the seasonal flu, human immunodeficiency virus (HIV), and Nipah virus.
Moderna wants to broaden its vaccine portfolio. Image source: Getty Images.
Source Fool.com